Result 1 - 10 of total 219
Western journal of medicine and surgery
2024 Volume 8, Issue 1, Page(s) 70–71
| Language | English |
|---|---|
| Publishing date | 2024-01-11 |
| Publishing country | United States |
| Document type | Journal Article |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
Journal of psychological medicine and mental pathology (London, England : 1875)
2017 Volume 1, Issue 1, Page(s) 88–97
| Language | English |
|---|---|
| Publishing date | 2017-09-14 |
| Publishing country | England |
| Document type | Journal Article |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
Journal of psychological medicine and mental pathology (London, England : 1848)
2017 Volume 7, Issue 26, Page(s) 291–296
| Language | English |
|---|---|
| Publishing date | 2017-09-14 |
| Publishing country | England |
| Document type | Journal Article |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
Journal of psychological medicine and mental pathology (London, England : 1875)
2017 Volume 2, Issue Pt 2, Page(s) 252–262
| Language | English |
|---|---|
| Publishing date | 2017-09-14 |
| Publishing country | England |
| Document type | Journal Article |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
Journal of psychological medicine and mental pathology (London, England : 1875)
2017 Volume 1, Issue 2, Page(s) 200–221
| Language | English |
|---|---|
| Publishing date | 2017-09-14 |
| Publishing country | England |
| Document type | Journal Article |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
Journal of psychological medicine and mental pathology (London, England : 1875)
2017 Volume 4, Issue Pt 2, Page(s) 230–255
| Language | English |
|---|---|
| Publishing date | 2017-09-14 |
| Publishing country | England |
| Document type | Journal Article |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.
Journal of the National Cancer Institute
2024 Volume 116, Issue 5, Page(s) 764–765
| MeSH term(s) | Humans ; Neoplasms/drug therapy ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/metabolism ; Blood Proteins/metabolism |
|---|---|
| Chemical Substances | Biomarkers, Tumor ; Blood Proteins |
| Language | English |
| Publishing date | 2024-03-15 |
| Publishing country | United States |
| Document type | Letter ; Journal Article |
| ZDB-ID | 2992-0 |
| ISSN | 1460-2105 ; 0027-8874 ; 0198-0157 |
| ISSN (online) | 1460-2105 |
| ISSN | 0027-8874 ; 0198-0157 |
| DOI | 10.1093/jnci/djae064 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Uh III Zs.131: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
The Lancet. Respiratory medicine
2021 Volume 10, Issue 2, Page(s) 149–157
Abstract: Background: Preserved ratio impaired spirometry (PRISm) is defined as a FEV: Methods: For this cohort analysis, we used data from the UKBiobank to assess PRISm prevalence, risk factors and associated symptoms, and associated comorbidities in a large ... ...
| Abstract | Background: Preserved ratio impaired spirometry (PRISm) is defined as a FEV Methods: For this cohort analysis, we used data from the UKBiobank to assess PRISm prevalence, risk factors and associated symptoms, and associated comorbidities in a large adult population. Participants with spirometry deemed acceptable by an investigator (best measure FEV Findings: Participants were recruited by UK Biobank between Dec 19, 2006, and Oct 10, 2010. We included 351 874 UK Biobank participants (189 247 women and 162 627 men) in our study, with a median follow-up of 9·0 years (IQR 8·0-10·0). 38 639 (11·0%) of 351 874 participants had PRISm at baseline. After adjustment, PRISm was strongly associated with obesity (odds ratio [OR] 2·40 [2·26-2·55], p<0·0001), current smoking (1·48 [1·36-1·62], p<0·0001), and patient reported doctor-diagnosed asthma (1·76 [1·66-1·88], p<0·0001). Other risk factors identified included female sex, being overweight, trunk fat mass, and trunk fat percentage. PRISm was strongly associated with symptoms and comorbidity including increased risk of breathlessness (adjusted OR 2·0 [95% CI 1·91-2·14], p<0·0001) and cardiovascular disease (adjusted OR 1·71 [1·64-1·83], p<0·0001 for heart attack). Longitudinal analysis showed that 241 (12·2%) of 1973 participants who had PRISm at baseline had transitioned to airflow obstruction consistent with COPD. PRISm was associated with increased all-cause mortality (adjusted hazard ratio 1·61 [95% CI 1·53-1·69], p<0·0001) versus control participants. Interpretation: PRISm was associated with breathlessness, multimorbidity, and increased risk of death, which does not seem to be explained by smoking, obesity, or existing lung disease. Although for many patients PRISm is transient, it is important to understand which individuals are at risk of progressive lung function abnormalities. Further research into the genetic, structural and functional pathophysiology of PRISm is warranted. Funding: UK Medical Research Council and University of Bristol. |
|---|---|
| MeSH term(s) | Adult ; Biological Specimen Banks ; Cohort Studies ; Female ; Forced Expiratory Volume ; Humans ; Lung ; Male ; Prevalence ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Risk Factors ; Spirometry ; United Kingdom/epidemiology ; Vital Capacity |
| Language | English |
| Publishing date | 2021-11-02 |
| Publishing country | England |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 2686754-0 |
| ISSN | 2213-2619 ; 2213-2600 |
| ISSN (online) | 2213-2619 |
| ISSN | 2213-2600 |
| DOI | 10.1016/S2213-2600(21)00369-6 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 7041: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
2023 Volume 20, Issue 1, Page(s) e1003988
Abstract: Background: Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be ... ...
| Abstract | Background: Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be attributable to confounding factors. In this study, we performed a drug target Mendelian randomisation (MR) analysis to evaluate the association of genetically proxied inhibition of LDL-c-lowering drug targets on risk of PrCa. Methods and findings: Single-nucleotide polymorphisms (SNPs) associated with LDL-c (P < 5 × 10-8) from the Global Lipids Genetics Consortium genome-wide association study (GWAS) (N = 1,320,016) and located in and around the HMGCR, NPC1L1, and PCSK9 genes were used to proxy the therapeutic inhibition of these targets. Summary-level data regarding the risk of total, advanced, and early-onset PrCa were obtained from the PRACTICAL consortium. Validation analyses were performed using genetic instruments from an LDL-c GWAS conducted on male UK Biobank participants of European ancestry (N = 201,678), as well as instruments selected based on liver-derived gene expression and circulation plasma levels of targets. We also investigated whether putative mediators may play a role in findings for traits previously implicated in PrCa risk (i.e., lipoprotein a (Lp(a)), body mass index (BMI), and testosterone). Applying two-sample MR using the inverse-variance weighted approach provided strong evidence supporting an effect of genetically proxied inhibition of PCSK9 (equivalent to a standard deviation (SD) reduction in LDL-c) on lower risk of total PrCa (odds ratio (OR) = 0.85, 95% confidence interval (CI) = 0.76 to 0.96, P = 9.15 × 10-3) and early-onset PrCa (OR = 0.70, 95% CI = 0.52 to 0.95, P = 0.023). Genetically proxied HMGCR inhibition provided a similar central effect estimate on PrCa risk, although with a wider 95% CI (OR = 0.83, 95% CI = 0.62 to 1.13, P = 0.244), whereas genetically proxied NPC1L1 inhibition had an effect on higher PrCa risk with a 95% CI that likewise included the null (OR = 1.34, 95% CI = 0.87 to 2.04, P = 0.180). Analyses using male-stratified instruments provided consistent results. Secondary MR analyses supported a genetically proxied effect of liver-specific PCSK9 expression (OR = 0.90 per SD reduction in PCSK9 expression, 95% CI = 0.86 to 0.95, P = 5.50 × 10-5) and circulating plasma levels of PCSK9 (OR = 0.93 per SD reduction in PCSK9 protein levels, 95% CI = 0.87 to 0.997, P = 0.04) on PrCa risk. Colocalization analyses identified strong evidence (posterior probability (PPA) = 81.3%) of a shared genetic variant (rs553741) between liver-derived PCSK9 expression and PrCa risk, whereas weak evidence was found for HMGCR (PPA = 0.33%) and NPC1L1 expression (PPA = 0.38%). Moreover, genetically proxied PCSK9 inhibition was strongly associated with Lp(a) levels (Beta = -0.08, 95% CI = -0.12 to -0.05, P = 1.00 × 10-5), but not BMI or testosterone, indicating a possible role for Lp(a) in the biological mechanism underlying the association between PCSK9 and PrCa. Notably, we emphasise that our estimates are based on a lifelong exposure that makes direct comparisons with trial results challenging. Conclusions: Our study supports a strong association between genetically proxied inhibition of PCSK9 and a lower risk of total and early-onset PrCa, potentially through an alternative mechanism other than the on-target effect on LDL-c. Further evidence from clinical studies is needed to confirm this finding as well as the putative mediatory role of Lp(a). |
|---|---|
| MeSH term(s) | Humans ; Male ; Proprotein Convertase 9/genetics ; Genome-Wide Association Study ; Cholesterol, LDL ; Polymorphism, Single Nucleotide ; Prostatic Neoplasms/genetics ; Testosterone ; Mendelian Randomization Analysis |
| Chemical Substances | PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) ; Cholesterol, LDL ; Testosterone (3XMK78S47O) |
| Language | English |
| Publishing date | 2023-01-03 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 2185925-5 |
| ISSN | 1549-1676 ; 1549-1277 |
| ISSN (online) | 1549-1676 |
| ISSN | 1549-1277 |
| DOI | 10.1371/journal.pmed.1003988 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
| Zs.A 6042: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
iScience
2023 Volume 26, Issue 6, Page(s) 106848
Abstract: Preclinical and genetic studies suggest that impaired glucose-dependent insulinotropic polypeptide receptor (GIPR) signaling worsens glycemic control. The relationship between GIPR signaling and the risk of cancers influenced by impaired glucose ... ...
| Abstract | Preclinical and genetic studies suggest that impaired glucose-dependent insulinotropic polypeptide receptor (GIPR) signaling worsens glycemic control. The relationship between GIPR signaling and the risk of cancers influenced by impaired glucose homeostasis is unclear. We examined the association of a variant in |
|---|---|
| Language | English |
| Publishing date | 2023-05-09 |
| Publishing country | United States |
| Document type | Journal Article |
| ISSN | 2589-0042 |
| ISSN (online) | 2589-0042 |
| DOI | 10.1016/j.isci.2023.106848 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.